Calcimate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcimate

Property Description
Active Ingredient Calcium Carbonate (CaCO3)
Form Oral Tablet, Chewable Tablet, Oral Suspension
Pharmacological Class Mineral Supplementation Agent, Calcium Salt
Common Use Essential Nutrient Provision; Gastric Acid Neutralization
Origin Inorganic Salt derived from natural mineral sources

Calcimate is a distinct pharmaceutical preparation classified as a Mineral Supplementation Agent and a widely accessible Over-the-Counter (OTC) Medication used to support the body's essential functions. This product belongs to the pharmacological category of Calcium Salts and is considered a Foundational Therapy for addressing mineral deficit, a role clinically recognized and widely supported by medical literature. Calcimate provides Essential Nutrient Provision and frequently offers the dual benefit of Gastric Acid Neutralization, distinguishing it from mineral-only supplements.

What Type of Medicine is Calcimate?

Calcimate is an OTC Medication and a Mineral Supplementation Agent derived from the Active Ingredient, Calcium Carbonate, serving as an available source of Elemental Calcium. The preparation’s classification reflects its primary use as an Electrolyte Replacement Agent in individuals requiring supplementary calcium. Its dual functionality as an antacid differentiates it within the mineral supplement market, offering a combination of systemic and localized benefits. The product is most commonly formulated for the Oral route of administration.

Composition, Forms, and Origin of Calcimate

The composition of Calcimate centers on Calcium Carbonate, which is an Inorganic Salt that is typically processed from purified mineral sources, ensuring its use as a pharmaceutical-grade Dietary Mineral. The preparation is readily available in various Pharmaceutical Preparations, most notably solid forms such as a Tablet or Chewable Tablet, often featuring flavorings to enhance patient acceptance. Furthermore, Calcimate is frequently provided as a Combination Product, pairing the Carbonate Salt with Vitamin D to facilitate efficient absorption of the Elemental Calcium.

The General Purpose of Calcimate

The general purpose of Calcimate is defined by its two core therapeutic benefits. Its primary function is to supply the necessary Calcium Ion to the body, supporting crucial processes like muscle and nerve function and promoting Bone Mineralization Support. Additionally, the chemical properties of Calcium Carbonate enable its rapid local effect of Gastric Acid Neutralization, which provides general relief from discomfort associated with excess stomach acid. This means the product can serve the typical use scenario of supplementing the diet of adults who also experience occasional mild heartburn.

Regulatory References

  1. Calcium Carbonate - StatPearls - NCBI Bookshelf
  2. Calcium - Health Professional Fact Sheet - NIH ODS

What side effects are possible with Calcimate?

Possible Side Effects and Safety Information

The safety profile of Calcimate (Calcium Carbonate) is defined by official regulatory documents, which categorize potential adverse effects primarily into gastrointestinal and metabolic disorders. This information is classified by frequency and grouped according to the standard regulatory System-Organ Classes.

Adverse Reactions and Frequency

The most frequently documented adverse reactions generally involve the digestive system. Regulatory classifications for occurrence include:

Classification Examples of Reactions
Rare Constipation, Flatulence, Nausea
Uncommon Hypercalcaemia (high blood calcium), Hypercalciuria (high urine calcium)
Very Rare Vomiting, Milk-alkali syndrome

Serious Adverse Reactions

While generally rare, regulatory documents highlight the potential for serious adverse effects, including Hypercalcaemia and its associated complications, such as Milk-alkali syndrome and the potential for Nephrolithiasis (kidney stones). These serious reactions are typically associated with prolonged use at high doses.

Population-Specific Safety Considerations

The official labeling includes specific restrictions and monitoring requirements for certain groups. Due to the risk of severe complications, use is generally restricted in individuals with pre-existing conditions like Hypercalcaemia, Hypercalciuria, or documented severe renal insufficiency. Furthermore, older adults undergoing long-term treatment are advised to have their serum calcium levels and renal function monitored, as this pattern of use increases the potential for adverse metabolic effects.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Calcimate (Calcium Carbonate) is primarily characterized by a state of hypercalcaemia, which refers to excessively high levels of calcium in the blood, as documented in official prescribing information. Manifestations can include common symptoms such as nausea, vomiting, constipation, and abdominal pain. Systemic signs often involve significant thirst (polydipsia), increased urination (polyuria), muscle weakness, and changes in mental state, including confusion or depression.

Officially documented severe outcomes include critical effects on major organ systems. These may involve renal insufficiency (impaired kidney function), the risk of an irregular heartbeat, and severe neurological events such as stupor or coma. Individuals with impaired renal function are specifically noted to be at a significantly increased risk for hypercalcaemia and related complications. Long-term, excessive intake is also a documented concern, potentially leading to the development of the Milk-alkali syndrome.

Regulatory agencies mandate immediate action when an overdose is suspected. Individuals must seek medical help right away and contact a Poison Control Center immediately. Management, as described in official documents, focuses on immediately discontinuing the product and providing supportive measures, including aggressive rehydration and close monitoring of serum calcium levels. In severe cases of hypercalcaemia, supportive procedures like specific diuretics or dialysis may be required.

Therapeutic Uses of Calcimate

What Calcimate Treats: Main Uses and Benefits

Calcimate is relevant across two key therapeutic domains. The product is generally used as a supplement to address mineral deficiency and for symptomatic relief of digestive issues.


Therapeutic Applications

The primary therapeutic benefit addresses two areas. It contributes to the maintenance of bone strength and systemic stability, and is commonly used to help with conditions like osteoporosis, osteopenia, and chronic hypocalcemia. It also helps address symptom clusters related to irritative states in the stomach, such as heartburn, acid indigestion, and sour stomach. In specialized contexts, it plays a role in managing high blood phosphate levels in Chronic Kidney Disease and may be part of symptomatic management for the risk of fractures.

This preparation provides supportive relief across scenarios involving foundational health needs and episodes of symptomatic discomfort.


Quick Fact

Quick Fact: Relief for Acid Indigestion This product assists with maintaining functional stability by addressing the imbalance caused by excess stomach acid, which contributes to improved day-to-day comfort during symptomatic periods of digestive upset.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcimate? — Official Regulatory Information

The eligibility profile for Calcimate is defined by strict exclusions, or contraindications, outlined in regulatory documents. The medication is absolutely prohibited for use in patients who have a known hypersensitivity or allergy to the active substance or any other component of the product.

Contraindicated Populations

Use is formally contraindicated in patients with pre-existing conditions that involve high levels of calcium or severe kidney dysfunction, including:

  • Hypercalcaemia (high blood calcium levels)
  • Hypercalciuria (excessive calcium in the urine)
  • Nephrolithiasis (kidney stones)
  • Nephrocalcinosis (calcification in the kidney)
  • Severe Renal Impairment (severe kidney dysfunction)
  • Hypervitaminosis D (excessive vitamin D levels)

Restricted and Non-Recommended Use

Official labeling contains specific rules for other patient groups:

  • Age-Related Eligibility: The product is not recommended for use in children and adolescents under 18 years of age.
  • Pregnancy and Lactation: The high-dose product is not recommended during pregnancy and breast-feeding; a lower-dosed product must be considered.
  • Renal Function: Patients with non-severe impaired renal function require close medical monitoring of calcium and phosphate levels during use to avoid soft tissue calcification.

What should I know about interactions with other medicines?

Calcimate (Calcium Carbonate) interacts with several medicinal products by altering their plasma exposure or through additive physiological effects, as documented in official regulatory sources.


Exposure-Modifying Interactions

Calcimate can significantly reduce the oral absorption of certain medicines, a non-systemic pharmacokinetic effect caused by chelation or changes to gastric pH. These interactions are officially documented for:

  • Antibiotics: Fluoroquinolones (e.g., Ciprofloxacin) and Tetracyclines (e.g., Doxycycline).
  • Osteoporosis Agents: Bisphosphonates (e.g., Alendronate, Risedronate).
  • Other Agents: Levothyroxine (a thyroid hormone) and Sotalol.

To mitigate this reduced exposure, regulatory information requires mandatory timing separation for these co-administered drugs. For instance, Levothyroxine must be separated by at least 4 hours, and Bisphosphonates by at least 30 minutes (Bisphosphonate first). Antibiotics in the Tetracycline and Fluoroquinolone classes require separation of several hours.


Pharmacodynamic Interactions

Official documents also detail additive systemic effects with other drug classes:

  • Thiazide Diuretics: Co-administration is documented to increase the risk of hypercalcemia due to the combined effect on serum calcium levels.
  • Cardiac Glycosides (e.g., Digoxin): Concomitant use increases the documented risk of cardiac arrhythmias.

Dietary Interference

Official documentation notes that dietary components such as Oxalic Acid (found in spinach and rhubarb) and Phytic Acid (found in bran and whole grains) can decrease the absorption of calcium from Calcimate itself.

Mechanism of Action

How Calcimate Works: Mechanism of Action


The mechanism of Calcimate is dual, involving both a localized chemical interaction and a systemic process of ion supply.

Direct Chemical Neutralization of Gastric Acidity

This action is a rapid, non-receptor-mediated acid-base reaction where the Calcium Carbonate chemically consumes Hydrochloric Acid ( HCl) within the stomach lumen. This buffering elevates the gastric pH level, leading to the inactivation of the pH-dependent enzyme Pepsin. The physiological consequence is a direct reduction of chemical stress upon the upper gastrointestinal mucosa.

Systemic Modulation of Calcium Homeostasis

Following conversion and absorption, elemental calcium is taken up by intestinal Ca^2+ transporters, increasing plasma Ca^2+ concentration. This engages the Calcium-Sensing Receptor ( CaSR) on the parathyroid gland, activating a negative feedback loop that suppresses Parathyroid Hormone ( PTH) secretion. This cascade influences bone remodeling and contributes to the regulation of the ionic environment required for nerve and muscle function.

Synergistic Enhancement of Absorption

In combined formulations, the Vitamin D metabolite acts as a genetic regulator that increases the expression of intestinal Ca^2+ transport proteins, such as Calbindin. This synergy increases the efficiency and capacity of Ca^2+ absorption, which affects the systemic delivery of the elemental ion to homeostatic mechanisms.

Dosage and Administration Information

How to Use Calcimate: Official Administration Guidelines

Calcimate, whose active ingredient is Calcium Carbonate, is administered strictly via the oral route for all approved forms, including tablets, chewable tablets, and suspensions. Proper usage is determined by the reason for taking the medicine, which dictates both the dose and frequency.


Administration Scope

Usage Context Dosing Schedule and Frequency
Symptomatic Relief (Antacid) The typical dose is 500 mg to 1000 mg per administration. Dosing is intermittent and taken as needed, with a labeled maximum daily limit generally not exceeding 7 to 8 grams.
Long-term Supplementation Maintenance doses are typically 500 mg to 1500 mg of elemental calcium daily. This amount is commonly administered in divided doses throughout the day to optimize absorption.

Procedural and Timing Instructions

Administration requires specific steps depending on the dosage form. Chewable tablets must be chewed thoroughly before swallowing, while oral suspensions must be shaken well prior to measurement. Furthermore, official instructions dictate that the intake of Calcimate must be separated by several hours from certain other oral medications, such as bisphosphonates or specific antibiotics, to prevent interference with their absorption.

The duration of use for self-treatment of symptoms at the maximum dose level is officially constrained to a maximum of two weeks. In contrast, its use for deficiency and adjunctive support therapies is generally defined as a long-term approach guided by clinical monitoring. For pediatric patients, age- and weight-specific doses are prescribed, and consultation is required before initiating use as an antacid in children under 12.

This protocol ensures the medicine is taken using the officially standardized method, frequency, and duration for its distinct label-based applications.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Research

Research has explored whether the drug may be associated with a reduction in symptoms of Condition A. Studies primarily focus on adults diagnosed with Condition A within the past five years.

  • Core Symptom Response: A large randomized control trial (RCT) examined whether the drug might be associated with an improvement in the Condition A Severity Score (CASS) over 12 weeks. The majority of studies examined whether it might be associated with a reduction in pain compared to standard care, but study protocols required strict participant adherence to the assigned regimen.
  • Long-Term Follow-up: Several open-label extension studies investigated sustained response in patients who continued treatment for up to two years. It is not yet clear whether the long-term benefit-risk profile is similar to the initial short-term findings, and evidence remains limited.
  • Early Intervention: Research has investigated whether the drug may be associated with rapid changes in symptoms in early-stage patients. Findings were mixed across different cohorts, and no definitive conclusion on early-stage specific benefit has been established.

Combination Therapy and Immunological Markers

The research also explored the role of the drug as part of a combination regimen.

  • Combination with Drug Y: Studies examined whether combining the drug with standard therapy (Drug Y) might be associated with a greater change in patient-reported quality of life compared to Drug Y alone. The combination's findings were not conclusive on whether it demonstrated greater effectiveness in the primary endpoints of most trials.
  • Inflammatory Markers: One study on combination therapy examined an association between the drug and changes in inflammatory markers (e.g., C-reactive protein). Researchers investigated whether the formulation may be associated with changes in patient outcomes.
  • Mechanism of Action: Overall, the evidence suggests that this drug may function by modulating the immune response, but the relationship between this possible function and clinical outcomes continues to be examined.

Frequently Asked Questions (FAQ)

Common questions about Calcimate (FAQ)


Q: How quickly does Calcimate start working?

Official product information describes two different speeds of action. The effect of neutralizing stomach acid is rapid, occurring shortly after administration. However, the systemic effect of providing calcium supplementation depends on the absorption process in the small intestine, which takes longer and can be enhanced by the presence of Vitamin D.


Q: Does Calcimate need to be taken at a specific time of day?

Official regulatory guidance describes administration as often being taken with food or immediately after a meal. This timing is understood to be because the stomach acid produced during digestion may help the body better absorb the calcium carbonate. This is descriptive information related to optimizing absorption.


Q: Can Calcimate be used by people with kidney issues?

According to official regulatory documents, Calcimate is formally prohibited for individuals with severe renal impairment (severe kidney dysfunction). For patients with non-severe kidney issues, the product is described as being used with caution, and close medical monitoring of serum calcium and phosphate levels is typically advised.


Q: What does the FDA say about Calcimate?

The Food and Drug Administration (FDA) regulates Calcimate (Calcium Carbonate) in the United States. It is classified by the agency as both an Over-the-Counter (OTC) medication and a Mineral Supplementation Agent.


Q: Does Calcimate interact with common pain relievers?

Official regulatory information indicates that Calcimate may interact with certain common pain relievers. The medicine may be associated with a decreased effect of Aspirin. Additionally, combining Calcimate with certain nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with an increased risk of digestive side effects. No known interactions are documented with Acetaminophen.


Q: Can Calcimate be taken with other supplements?

Official guidelines for mineral supplementation suggest that Calcimate may affect how the body absorbs other minerals. Specifically, the absorption of supplements containing Iron, Zinc, and Magnesium may be reduced if taken simultaneously with Calcimate. Official guidelines mention that separating doses is a common consideration to avoid this kind of interaction.


Q: Where can I find reliable, official information about Calcimate studies?

Reliable, authoritative information about Calcimate is generally found on government health and drug authority websites. These sources include the FDA’s Drugs@FDA database, the NIH DailyMed service, and the European Medicines Agency (EMA) Public Assessment Reports.


Q: What happens if I miss a dose of Calcimate?

Official administration protocols describe the recommended procedure for a missed dose. The protocol indicates that if a dose is missed, it is generally recommended to take it as soon as it is remembered. However, if it is almost time for your next scheduled dose, the instruction is to skip the missed dose. The protocol specifically advises against taking double or extra doses.


Q: Is it normal to feel a change in appetite while on Calcimate?

A change in appetite, specifically a loss of appetite, has been documented as a very rare potential adverse effect in official safety profiles. This change is often associated with the uncommon metabolic reaction of having high calcium levels in the blood.


Q: What should I do if I accidentally take too much Calcimate?

Official regulatory information specifies the protocol to follow in the event of an accidental overdose. The protocol indicates that immediately contacting a poison control center or seeking emergency medical attention is necessary.


Q: Does Calcimate contain gluten or common allergens?

The official regulatory label details the active ingredient but does not universally list all excipients, such as gluten, for every specific product brand. However, some forms, like certain chewable tablets, are noted to contain Phenylalanine, which carries a specific warning for individuals with Phenylketonuria (PKU). Confirming the complete list of inactive ingredients and allergens on the specific product's packaging is generally necessary.


Q: Is Calcimate known to cause headaches?

Headaches have been documented in official safety information as a very rare potential adverse event related to the nervous system. Furthermore, headaches can be a symptom associated with the uncommon condition of having high calcium levels in the blood.


Q: Can Calcimate affect mood?

Official regulatory sources indicate that mood changes may occur as a sign of high calcium levels in the blood, a condition known as hypercalcemia. Hypercalcemia is classified as an uncommon potential adverse reaction associated with this product.


Q: Is Calcimate only for women?

Official indications for Calcimate include mineral deficiency conditions that affect both men and women. While it is commonly used for conditions like postmenopausal bone health in women, its use is also documented for other conditions such as hypocalcemia that are not gender-specific.


Q: Can I drive or operate machinery after taking Calcimate?

Regulatory documents do not contain explicit warnings against driving or operating machinery. However, if potential adverse effects associated with high calcium levels occur—such as confusion, dizziness, or headache—the ability to perform these tasks may be affected.


Q: Does taking Calcimate affect lab test results?

Taking Calcimate directly affects the body’s levels of calcium and phosphate. Official product labeling describes that patients undergoing long-term use require the monitoring of their serum calcium and renal function, which relies on accurate lab tests.


Q: How is Calcimate eliminated from the body?

The body processes Calcimate in two ways. Unabsorbed calcium is eliminated directly through the feces. The absorbed calcium is primarily excreted in the urine, a process regulated by hormones, with a small amount also eliminated as carbon dioxide through the lungs.

How should Calcimate be stored and disposed of?

Official Storage and Disposal Requirements

Calcimate (Calcium Carbonate) must be stored strictly according to regulatory labeling to maintain product stability. Tablets and chewable tablets require controlled room temperature, typically between 15 C and 30 C. The product must be protected from moisture and high humidity, necessitating that the container remain tightly closed and that the product be stored in its original package.

Specific handling rules include the instruction to not freeze the oral suspension form. A mandatory safety requirement is to keep out of reach of children.

Disposal of unused or expired product must be done in accordance with local and federal regulations, and it is explicitly stated that the material should not be released into the environment or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcimate found in:

A-Z Index: